Stock·NASDAQ·Financial Services
CME Group Inc. (CME)
- Market cap
- $104.08B
- P/E
- 23.58
- Dividend yield
- 3.90%
- Street target
- $297.50median of 17 analysts
- 52-week range
- $218.31 $329.16
The short version
Where CME stands today, in four lines, and what CleaRank Financial AI makes of it.
CME at a glance
CME Group Inc. (CME): Hold, 55/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($273.17 and $278.60).
- Earnings CME beat estimates in 3 of its last 5 quarters, and the stock rose the next day every time.
- Insiders Insiders sold $38.8M and bought $666K over the last 18 months.
- Valuation P/E of 23.6 against 16.5 for the Financial Services sector: a premium to peers (+43%).
Figures as of October 16, 2026.
CleaRank Financial AI
CME Group Inc. (CME) is trading at $289.46, above its 50-day and 200-day moving averages ($273.17 and $278.60), indicating positive short-to-medium term momentum.
The company's financial health is strong, with a profit margin of 63.44% and a return on equity of 15.80%, outperforming sector averages in profitability. However, recent insider activity shows a net seller position, with $38.8M in total sales versus $666K in total purchases, signaling a 'Moderate Sell Signal' from insiders. The median analyst price target of $297.5 suggests a modest 2.8% upside from the current price. While revenue growth is projected at 8.00% for the current year, future growth estimates show a slight deceleration. The primary risk lies in the mixed analyst sentiment and insider selling, which could limit significant upward price movement despite strong operational performance.
Only on CleaRank
Figures we compute ourselves from CME's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $289.46 is 6.0% above the 50-day simple moving average of $273.17.Price above its 200-day average ›
The price is 3.9% above the 200-day simple moving average of $278.60.50-day average above the 200-day ›
The 50-day average ($273.17) is 1.9% below the 200-day average ($278.60), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 64% of its 52-week range, between $218.31 and $329.16.
CME share price
Pick a period: each tab shows how far CME has moved over it, to the last close.
Today's trading
Where CME sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 23.58 is 42.9% above the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 14.80 is 289.3% above the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $4.3B on revenue of $6.8B, a net margin of 63.1%.Beat estimates in most recent reports ›
CME beat the EPS estimate in 3 of its last 5 reports.Pays a dividend ›
The trailing dividend yield is 3.90%, or $11.30 a share a year.
Key statistics
The headline figures for CME.
As of October 16, 2026, CME trades at $289.46, with a market value of $104.08B, a P/E ratio of 23.58 and a dividend yield of 3.90%.
What the numbers say
CleaRank Financial AI's reading of CME's valuation, growth and risks.
CME Group Inc. exhibits strong profitability with a net profit margin of 63.44% and an operating margin of 65.04%, significantly exceeding the sector median of 13.8% for return on equity.
Its price-to-sales ratio is 14.80, which is higher than the sector median of 3.8, suggesting a premium valuation. The company's debt-to-equity ratio stands at a low 0.15, indicating a healthy balance sheet with minimal leverage. While the company demonstrates superior operational efficiency and profitability, its valuation metrics like P/E ratio (23.58) are above the sector average (16.5). Revenue growth for the current year is projected at 8.00%, with a slight slowdown expected in the next year. The strong margins and low debt provide a solid foundation, but the premium valuation warrants caution.
CME against the Financial Services sector
How CME compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: CME trades at a significant premium to sector peers (+43%), suggesting market expectations for superior growth or market position.
Return vs IAI: Since May 5, 2025, CME has gained 2.4% against a gain of 21.3% for IAI.
Performance against IAI
CME and the Financial Services sector fund over the same days.
Revenue and earnings
How much CME sells, and how much of it becomes profit.
Revenue growth: Revenue grew 6.4% in FY2025 to $6.5B, from $6.1B a year earlier.
Profit margin: The net margin was 62.5% in FY2025, up from 57.5% the year before.
Profitable: CME earned $4.1B in FY2025.
Earnings reality check
Did CME beat what analysts expected, and how did the stock react?
Earnings record: CME beat the analyst estimate in 3 of the last 5 quarters.
Market reaction: The stock rose in the first session after every beat.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Apr 22, 2026after close | $3.37 | $3.36 | -0.30% | -0.08% | +0.55% |
| Jul 23, 2025after close | $2.92 | $2.96 | +1.37% | +0.25% | +0.46% |
| Apr 23, 2025after close | $2.81 | $2.80 | -0.36% | +0.68% | +5.97% |
| Feb 12, 2025after close | $2.45 | $2.52 | +2.86% | +0.46% | -0.26% |
| Oct 23, 2024after close | $2.65 | $2.68 | +1.13% | +1.12% | +0.05% |
Reports after April 22, 2026 are not yet in our data.
As of October 16, 2026, CME has beaten the analyst EPS estimate in 3 of its last 5 reported quarters and rose in the first trading session after every one of those beats; its most recent report in our data, on April 22, 2026, came in 0.30% below the estimate and the stock moved -0.08% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 68.3, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 68.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CME
The score, the reasoning behind it, and what could move the price next.
CME Group Inc. is currently trading above its 50-day SMA of $273.17 and its 200-day SMA of $278.60, indicating an uptrend.
The 14-day RSI is at 68.28, signaling bullish momentum without being overbought. The MACD is positive at 3.07, further supporting upward price action. Key support levels are near the 50-day SMA, while resistance is implied by the current trading range and the median analyst target price. Volume on the latest trading day was 2.08 million shares, about 8.1% above the average volume, suggesting increased investor interest. The stochastic oscillator is at 97.56, indicating the stock is in overbought territory, which could precede a short-term pullback. However, the overall chart structure and moving average positioning suggest continued strength in the medium term.
Strong Revenue Growth Projections ›
Current year revenue growth is estimated at 8.00%, with next quarter projected at 5.00%, indicating sustained demand for CME's services.
Source: Wall Street EstimatesPositive Technical Momentum ›
CME Group Inc. is trading above its 50-day and 200-day moving averages ($273.17 and $278.60), with a bullish RSI of 68.28, suggesting continued upward price action.
Source: Technical Analysis
Moderate Insider Selling Signal ›
Insiders have sold $38.8 million worth of stock versus $666.2 thousand in purchases, resulting in a 'Moderate Sell Signal' that could weigh on sentiment.
Source: Insider TransactionsConsistent Dividend Payout ›
The company offers a dividend yield of 3.90%, providing a stable income stream for shareholders, which can buffer against price volatility.
Source: Dividend Data
- The stock is trading above its 50-day and 200-day moving averages ($273.17 and $278.60), indicating positive technical momentum, but the stochastic oscillator is overbought, suggesting a potential short-term pause or pullback.
- With a dividend yield of 3.90%, CME Group Inc. can be considered for income-focused portfolios, but balance this with the moderate upside potential and valuation concerns.
Technical indicators
Momentum and trend for CME, from its daily closes.
As of October 16, 2026, with CME at $289.46, its 14-day RSI is 68.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $273.17 and its 200-day is $278.60.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CME moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, CME's 1-year correlation of daily returns is -0.10 with S&P 500 (SPY), -0.19 with Nasdaq 100 (QQQ), +0.03 with Bitcoin (BTC) and +0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
8 of 17 analysts rate it a buy or strong buy, 6 a hold and 3 a sell.Median target above the price ›
The median 12-month target of $297.50 is 2.8% above the price.More buy ratings than three months ago ›
8 of 17 rate it a buy now, against 9 of 16 three months ago.
CME Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | Morgan Stanley | Maintains | Overweight |
| Oct 7, 2026 | Barclays | Maintains | Equal-Weight |
| Oct 5, 2026 | UBS | Maintains | Neutral |
| Oct 5, 2026 | TD Cowen | Maintains | Buy |
| Oct 2, 2026 | Wells Fargo | Initiates | Overweight |
| Sep 28, 2026 | TD Cowen | Reiterates | Buy |
As of October 16, 2026, 17 Wall Street analysts cover CME: 8 rate it a buy or strong buy, 6 a hold and 3 a sell or strong sell. Their 12-month price targets range from $217.00 to $337.00, with a median of $297.50, 2.8% above the price of $289.46.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CME trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CME's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CME tends to move, against the market and on its own.
The long record
CME's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.39% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 31.7%, from March 2022 to October 2022, regained by October 2024.Most 1-year holds ended higher ›
78% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $40,799, against $42,525 in the S&P 500 (SPY).
CME Drawdowns & Recovery
As of October 16, 2026, CME's worst peak-to-trough fall over the last 10 years with dividends reinvested was -31.7% (March 2022 to October 2022); it regained that peak by October 2024, 24 months after the low, and 78% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CME in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CME trailed the S&P 500 over this period: $40,799 against $42,525.
A $10,000 investment in CME in October 2016 would be worth about $40,799 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CME, and which have not.
Strongest month, November: an average of +4.99%, up in 9 of 10 years.
Weakest month, March: an average of -2.46%, up in 4 of 10 years.
This month, October: has averaged +0.39%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CME's strongest calendar month has been November (average +4.99%, up in 9 of 10 years) and its weakest March (average -2.46%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CME, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CME today could grow to about $21,641 by 2036 in the base case, with a 90th-percentile outcome near $58,641 and a 10th-percentile outcome around $7,987. The simulation models price only; at today's 3.90% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CME Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $394 for CME by 2030 in the base case, from $289 today (1.4x over 4 years). The 10th-percentile path ends near $210. These are outcomes of a Monte Carlo simulation run on CME's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $228 | $313 | $429 | |
| 2028 | $216 | $338 | $528 | |
| 2029 | $211 | $365 | $630 | |
| 2030 | $210 | $394 | $740 | |
| 2031 | $210 | $426 | $862 |
Method: a lognormal simulation of CME's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CME insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $666K on the open market and sold $38.8M.
As of October 16, 2026, CME insiders reported 27 open-market sales worth $38.8M and 4 open-market purchases worth $666K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | William R Shepard
Director
|
Buy | 292 | $78.6K |
| Sep 15, 2026 | Derek Louis Sammann
Officer
|
Grant | 2.9K | $787.9K |
| Sep 15, 2026 | Kendal L Vroman
Officer
|
Grant | 2.6K | $713.0K |
| Sep 14, 2026 | Elizabeth A Cook
Director
|
Sell | 500 | $140.1K |
| Sep 10, 2026 | Terrence A Duffy
Chief Executive Officer
|
Sell | 15.0K | $4.1M |
| Jun 25, 2026 | Kathryn Benesh
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Timothy S Bitsberger
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Charles P Carey
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Elizabeth A Cook
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Bryan T Durkin
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Harold Eugene Ford Jr
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Martin J Gepsman
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | William W Hobert
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Daniel G Kaye
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Phyllis M Lockett
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Deborah J Lucas
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Patrick W Maloney
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Patrick J Mulchrone
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Rahael Seifu
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | William R Shepard
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | William R Shepard
Director
|
Buy | 339 | $78.2K |
| Jun 25, 2026 | Howard J Siegel
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Dennis A. Suskind
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Robert J. Tierney Jr
Director
|
Grant | 645 | $145.1K |
| May 18, 2026 | Hilda Harris Piell
Officer
|
Sell | 5.8K | $1.8M |
| May 15, 2026 | Terrence A Duffy
Chief Executive Officer
|
Sell | 35.0K | $10.4M |
| Mar 26, 2026 | William R Shepard
Director
|
Buy | 1.5K | $437.1K |
| Mar 17, 2026 | Jonathan L Marcus
General Counsel
|
Sell | 3.3K | $1.1M |
| Mar 17, 2026 | Jonathan L Marcus
Officer
|
Sell | 3.3K | $1.0M |
| Mar 13, 2026 | Sunil Kiran Cutinho
Chief Technology Officer
|
Grant | 8.3K | $2.6M |
| Mar 13, 2026 | Terrence A Duffy
Chief Executive Officer
|
Grant | 62.9K | $19.6M |
| Mar 13, 2026 | Lynne Fitzpatrick
Chief Executive Officer
|
Grant | 5.5K | $1.7M |
| Mar 13, 2026 | Jonathan L Marcus
General Counsel
|
Grant | 5.3K | $1.6M |
| Mar 13, 2026 | Timothy Francis Mccourt
Officer
|
Grant | 5.5K | $1.7M |
| Mar 13, 2026 | Hilda Harris Piell
Officer
|
Grant | 7.1K | $2.2M |
| Mar 13, 2026 | Derek Louis Sammann
Officer
|
Grant | 8.3K | $2.6M |
| Mar 13, 2026 | Suzanne Sprague
Chief Operating Officer
|
Grant | 5.5K | $1.7M |
| Mar 13, 2026 | Jack J Tobin
Officer
|
Grant | 608 | $189.3K |
| Mar 13, 2026 | Kendal L Vroman
Officer
|
Grant | 7.1K | $2.2M |
| Mar 13, 2026 | Julie Winkler
Officer
|
Grant | 8.3K | $2.6M |
| Mar 12, 2026 | Kendal L Vroman
Officer
|
Sell | 5.2K | $1.6M |
| Mar 11, 2026 | Jack J Tobin
Officer
|
Grant | 105 | - |
| Mar 6, 2026 | Elizabeth A Cook
Director
|
Sell | 1.0K | $320.0K |
| Feb 23, 2026 | Bryan T Durkin
Director
|
Sell | 4.2K | $1.3M |
| Feb 20, 2026 | Martin J Gepsman
Director
|
Sell | 300 | $91.8K |
| Feb 6, 2026 | Dennis A Suskind
Director
|
Sell | 748 | $224.4K |
| Dec 11, 2025 | Terrence A Duffy
Chief Executive Officer
|
Sell | 25.0K | $6.7M |
| Nov 20, 2025 | Derek Louis Sammann
Officer
|
Sell | 7.2K | $2.0M |
| Nov 7, 2025 | Hilda Harris Piell
Officer
|
Grant | 973 | - |
| Nov 3, 2025 | Harold Eugene Ford Jr
Director
|
Sell | 1.0K | $263.5K |
| Sep 18, 2025 | Jonathan L Marcus
General Counsel
|
Sell | 392 | $102.7K |
| Sep 16, 2025 | Timothy Francis Mccourt
Officer
|
Sell | 379 | $98.5K |
| Sep 16, 2025 | Jonathan L Marcus
General Counsel
|
Sell | 376 | $97.4K |
| Sep 15, 2025 | Sunil Kiran Cutinho
Chief Technology Officer
|
Grant | 3.0K | $787.9K |
| Sep 15, 2025 | Michael G Dennis
Officer
|
Grant | 2.6K | $675.0K |
| Sep 15, 2025 | Terrence A Duffy
Chief Executive Officer
|
Grant | 23.2K | $6.0M |
| Sep 15, 2025 | Lynne Fitzpatrick
President
|
Grant | 4.3K | $1.1M |
| Sep 15, 2025 | Jonathan L Marcus
General Counsel
|
Grant | 2.5K | $637.8K |
| Sep 15, 2025 | Timothy Francis Mccourt
Officer
|
Grant | 2.8K | $712.3K |
| Sep 15, 2025 | Hilda Harris Piell
Officer
|
Grant | 2.6K | $675.0K |
| Sep 15, 2025 | Derek Louis Sammann
Officer
|
Grant | 3.0K | $787.9K |
| Sep 15, 2025 | Suzanne Sprague
Officer
|
Grant | 3.0K | $787.9K |
| Sep 15, 2025 | Jack J Tobin
Officer
|
Grant | 1.5K | $400.2K |
| Sep 15, 2025 | Kendal L Vroman
Chief Technology Officer
|
Grant | 2.6K | $675.0K |
| Sep 15, 2025 | Julie Winkler
Officer
|
Grant | 3.0K | $787.9K |
| Aug 26, 2025 | Sunil Kiran Cutinho
Chief Technology Officer
|
Sell | 11.9K | $3.2M |
| Jun 25, 2025 | Kathryn Benesh
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Timothy S Bitsberger
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Charles P Carey
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Elizabeth A Cook
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Bryan T Durkin
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Harold Eugene Ford Jr
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Martin J Gepsman
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | William W Hobert
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Daniel G Kaye
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Phyllis M Lockett
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Deborah J Lucas
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Patrick W Maloney
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Patrick J Mulchrone
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Rahael Seifu
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | William R Shepard
Director
|
Buy | 267 | $72.3K |
| Jun 25, 2025 | William R Shepard
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Howard J Siegel
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Dennis A Suskind
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Robert J. Tierney Jr
Director
|
Grant | 532 | $145.3K |
| Jun 10, 2025 | Charles P Carey
Director
|
Sell | 500 | $132.7K |
| May 22, 2025 | Daniel G Kaye
Director
|
Sell | 500 | $141.2K |
| May 20, 2025 | Jonathan L Marcus
General Counsel
|
Sell | 390 | $108.2K |
| May 19, 2025 | Phyllis M Lockett
Director
|
Sell | 1.1K | $294.6K |
| May 15, 2025 | Charles P Carey
Director
|
Sell | 3.0K | $817.7K |
| May 15, 2025 | Martin J Gepsman
Director
|
Sell | 300 | $82.0K |
| May 5, 2025 | Derek Louis Sammann
Officer
|
Sell | 4.7K | $1.3M |
| Apr 29, 2025 | Dennis A Suskind
Director
|
Sell | 1.0K | $271.3K |
| Apr 25, 2025 | Larry G Gerdes
Director
|
Sell | 4.0K | $1.1M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.